Anderson MG - Search Results

1

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.

Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB. Wang J, et al. Among authors: anderson mg. Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573171

2

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB. Wang J, et al. BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z. BMC Cancer. 2016. PMID: 26879245 Free PMC article.

3

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.

Vaidya KS, Mitten MJ, Zelaya-Lazo AL, Oleksijew A, Alvey C, Falls HD, Mishra S, Palma J, Ansell P, Phillips AC, Reilly EB, Anderson M, Boghaert ER. Vaidya KS, et al. J Neurooncol. 2021 Apr;152(2):233-243. doi: 10.1007/s11060-021-03703-z. Epub 2021 Jan 30. J Neurooncol. 2021. PMID: 33517558

4

A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

Vaidya KS, Oleksijew A, Tucker LA, Pappano WN, Anderson MG, Grinnell CM, Zhang Q, Heighton SJ, Mitten MJ, Mishra S, Palma JP, Wang J, Reilly EB, Boghaert ER. Vaidya KS, et al. Among authors: anderson mg. Pharmacology. 2017;100(5-6):229-242. doi: 10.1159/000478663. Epub 2017 Jul 26. Pharmacology. 2017. PMID: 28743107

5

Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.

Anderson MG, Falls HD, Mitten MJ, Oleksijew A, Vaidya KS, Boghaert ER, Gao W, Palma JP, Cao D, Chia PL, John T, Gan HK, Scott AM, Reilly EB. Anderson MG, et al. Mol Cancer Ther. 2020 Oct;19(10):2117-2125. doi: 10.1158/1535-7163.MCT-20-0149. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847977

6

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.

Anderson MG, Zhang Q, Rodriguez LE, Hecquet CM, Donawho CK, Ansell PJ, Reilly EB. Anderson MG, et al. BMC Cancer. 2021 Jun 9;21(1):681. doi: 10.1186/s12885-021-08403-5. BMC Cancer. 2021. PMID: 34107902 Free PMC article.

7

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.

Shah OJ, Lin X, Li L, Huang X, Li J, Anderson MG, Tang H, Rodriguez LE, Warder SE, McLoughlin S, Chen J, Palma J, Glaser KB, Donawho CK, Fesik SW, Shen Y. Shah OJ, et al. Among authors: anderson mg. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12634-9. doi: 10.1073/pnas.0913615107. Epub 2010 Jun 28. Proc Natl Acad Sci U S A. 2010. PMID: 20616035 Free PMC article.

8

Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.

Li J, Anderson MG, Tucker LA, Shen Y, Glaser KB, Shah OJ. Li J, et al. Among authors: anderson mg. Cell Death Differ. 2009 Mar;16(3):498-511. doi: 10.1038/cdd.2008.174. Epub 2008 Dec 12. Cell Death Differ. 2009. PMID: 19079141

9

Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.

Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, Niquette A, Li J, Bouska JJ, Wang G, Semizarov D, Albert DH, Donawho CK, Glaser KB, Shah OJ. Guo J, et al. Among authors: anderson mg. Pharmacogenomics J. 2009 Apr;9(2):90-102. doi: 10.1038/tpj.2008.20. Epub 2009 Feb 3. Pharmacogenomics J. 2009. PMID: 19188929

10

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. Tse C, et al. Among authors: anderson mg. Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836. Cancer Res. 2008. PMID: 18451170

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

234 results

Search Page